Literature DB >> 33407851

A solitary brain metastasis as the only site of recurrence of HR positive, HER2 negative breast cancer: a case report and review of the literature.

Sandipkumar H Patel1, Yoshihito David Saito2, Zaibo Li3, Bhuvaneswari Ramaswamy1,4, Andrew Stiff4, Mahmoud Kassem1, Robert Wesolowski5,6.   

Abstract

BACKGROUND: Breast cancer is one of the most common causes of brain metastases. However, the presence of isolated central nervous system (CNS) metastatic disease early in the course of disease relapse is a rare event in cases of hormone receptor positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer. CASE <br> PRESENTATION: We summarize the clinical course of a pre-menopausal, 39-year old Caucasian female with history of operable, hormone receptor positive, HER2 negative breast cancer who was initially treated with curative-intend therapy but who unfortunately developed solitary metastatic lesion in the left thalamus. A biopsy of the lesion confirmed the presence of hormone receptor positive, HER2 negative metastatic breast cancer. Patient's CNS metastases continued to progress without any evidence of metastatic disease outside of the central nervous system and she eventually passed away about 5 years after the date of her initial diagnosis and 18 months following the diagnosis with brain metastasis. <br> CONCLUSION: Based on our case, although rare, patients with treated, operable, hormone receptor positive, HER2 negative breast cancer can present with solitary brain metastasis as the only sign of disease recurrence.

Entities:  

Keywords:  Brain metastases; Breast cancer; Chemotherapy; HER2; Hormone receptors

Mesh:

Year:  2021        PMID: 33407851      PMCID: PMC7789360          DOI: 10.1186/s13256-020-02615-2

Source DB:  PubMed          Journal:  J Med Case Rep        ISSN: 1752-1947


  23 in total

Review 1.  The necessity of intrathecal chemotherapy for the treatment of breast cancer patients with leptomeningeal metastasis: A systematic review and pooled analysis.

Authors:  Yen-Chien Lee; Chung-Cheng Hsieh; Jen-Pin Chuang; Chung-Yi Li
Journal:  Curr Probl Cancer       Date:  2017-07-12       Impact factor: 3.187

2.  Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study.

Authors:  Rashmi Murthy; Virginia F Borges; Alison Conlin; Jorge Chaves; Marc Chamberlain; Todd Gray; Alex Vo; Erika Hamilton
Journal:  Lancet Oncol       Date:  2018-05-24       Impact factor: 41.316

Review 3.  Preclinical approaches to study the biology and treatment of brain metastases.

Authors:  William Cruz-Muñoz; Robert S Kerbel
Journal:  Semin Cancer Biol       Date:  2010-12-13       Impact factor: 15.707

4.  Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis.

Authors:  Qi Shen; Aysegul A Sahin; Kenneth R Hess; Dima Suki; Kenneth D Aldape; Raymond Sawaya; Nuhad K Ibrahim
Journal:  Oncologist       Date:  2015-03-23

5.  Subtypes of breast cancer show preferential site of relapse.

Authors:  Marcel Smid; Yixin Wang; Yi Zhang; Anieta M Sieuwerts; Jack Yu; Jan G M Klijn; John A Foekens; John W M Martens
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis.

Authors:  Kadri Altundag; Melissa L Bondy; Nadeem Q Mirza; Shu-Wan Kau; Kristine Broglio; Gabriel N Hortobagyi; Edgardo Rivera
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

7.  Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.

Authors:  Thomas Bachelot; Gilles Romieu; Mario Campone; Véronique Diéras; Claire Cropet; Florence Dalenc; Marta Jimenez; Emilie Le Rhun; Jean-Yves Pierga; Anthony Gonçalves; Marianne Leheurteur; Julien Domont; Maya Gutierrez; Hervé Curé; Jean-Marc Ferrero; Catherine Labbe-Devilliers
Journal:  Lancet Oncol       Date:  2012-11-02       Impact factor: 41.316

8.  Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment.

Authors:  Anna Niwińska
Journal:  Clin Exp Metastasis       Date:  2016-05-25       Impact factor: 5.150

Review 9.  Management of solitary and multiple brain metastases from breast cancer.

Authors:  Addison Willett; J Ben Wilkinson; Chirag Shah; Minesh P Mehta
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Apr-Jun

10.  Stereotactic radiosurgery combined with nivolumab or Ipilimumab for patients with melanoma brain metastases: evaluation of brain control and toxicity.

Authors:  Giuseppe Minniti; Dimitri Anzellini; Chiara Reverberi; Gian Carlo Antonini Cappellini; Luca Marchetti; Federico Bianciardi; Alessandro Bozzao; Mattia Osti; Pier Carlo Gentile; Vincenzo Esposito
Journal:  J Immunother Cancer       Date:  2019-04-11       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.